

## Improving Savings and the Member Experience with Genetic Benefit Management

State of Kansas - Payer 41000

CY 2009

Utilization of Genetic Benefit Testing Drugs

Drug Name	Category	New Utilizers in Reporting Period		All Utilizers in Reporting Period	
		Utilizers	Gross Spend	Utilizers	Gross Spend
Ziagen (Abacavir)	PBM	.	.	1	\$1,491
Imuran (Azathioprine)	PBM	42	\$9,395	121	\$51,410
Tegretol (Carbamazepine)	PBM	83	\$9,549	196	\$65,032
Plavix (Clopidogrel)	PBM	308	\$220,047	837	\$925,988
Nolvadex (Tamoxifen)	PBM	40	\$3,771	120	\$17,563
Tabloid (Thioguanine)	PBM	1	\$671	1	\$671
Sprycel (Dasatinib)	Specialty	1	\$6,325	1	\$6,325
Tarceva (Erlotinib)	Specialty	6	\$39,069	6	\$39,069
Gleevec (Imatinib)	Specialty	5	\$92,673	9	\$292,845
Tykerb (Lapatinib)	Specialty	.	.	1	\$26,566
Tasigna (Nilotinib)	Specialty	.	.	1	\$51,305
Copegus (Peginterferon A)	Specialty	11	\$19,192	17	\$31,263
Pegasys (Ribavirin)	Specialty	5	\$53,828	10	\$111,098
Total		496	\$454,521	1,305	\$1,620,628
% of Client Total		0.7%	0.6%	1.7%	2.0%

### Pharmacogenomics

- Combines pharmacology and genetics to inform effective and safe prescribing decisions tailored to the individual
- Helps ensure members are on the right drug therapy that meets their unique genetic profile
- Pharmacogenomic testing can determine whether a specific medication therapy is likely to be effective or potentially harmful

### Genetic Benefit Management

1. Reduce inappropriate use and risk associated with trial-and-error approach
2. Improve health outcomes through greater accuracy and precision in drug therapy
3. Reduce overall healthcare costs
4. Provide access to the best test at competitive rates

The Food and Drug Administration has identified 30+ valid biomarkers, where a genetic test may help inform an Rx decision.<sup>1</sup>

Utilizers are unique for each drug (by gpi).

Some drugs may include other brand names.

A new utilizer is someone who did not have an Rx in the 6 months prior to the evaluation period.

<sup>1</sup> <http://www.fda.gov/downloads/drugs/scienceresearch/researchareas/pharmacogenetics/ucm085505.pdf> - accessed 1/202009

Source: CVS Caremark Analytic Consulting Services.

©2010 Caremark. All rights reserved. CVS Caremark Analytic Consulting Services.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark.

